Jeffrey S. Parkin

Array ( [id] => 17719126 [patent_doc_number] => 20220211845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => DNA ENCODED IL-36 GAMMA AS AN ADJUVANT [patent_app_type] => utility [patent_app_number] => 17/609451 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17143040 [patent_doc_number] => 20210311053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => MEASURING ANALYTES IN BIOLOGICAL SAMPLES [patent_app_type] => utility [patent_app_number] => 16/868480 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16868480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18233210 [patent_doc_number] => 11597759 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Multispecific antibodies that target HIV GP120 and CD3 [patent_app_type] => utility [patent_app_number] => 16/867924 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56224 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16656084 [patent_doc_number] => 20210052720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => CAP260, CAP174 AND K0224 HIV-1 ENVELOPES, PEPTIDE AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/862207 [patent_app_country] => US [patent_app_date] => 2020-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19274447 [patent_doc_number] => 12024558 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitors and ART [patent_app_type] => utility [patent_app_number] => 16/857715 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 8 [patent_no_of_words] => 17473 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704561 [patent_doc_number] => 20220204567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => RECOMBINANT INFLUENZA ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/594576 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18369353 [patent_doc_number] => 11649511 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Multiplex PCR method for the detection of SARS-CoV-2 [patent_app_type] => utility [patent_app_number] => 16/760945 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 14 [patent_no_of_words] => 4639 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359439 [patent_doc_number] => 20200316190 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => PSGL-1 (P-SELECTIN GLYCOPROTEIN LIGAND-1) TO INACTIVATE ALL ENVELOPED VIRUSES FOR PRODUCING LIVE-ATTENUATED VACCINES [patent_app_type] => utility [patent_app_number] => 16/838264 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16838264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17642248 [patent_doc_number] => 20220169986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => MULTI-RESPIRATORY VIRUS ANTIGEN-SPECIFIC T CELLS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY [patent_app_type] => utility [patent_app_number] => 17/593747 [patent_app_country] => US [patent_app_date] => 2020-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17783 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17593747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17741481 [patent_doc_number] => 11389527 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-19 [patent_title] => Methods of inducing an immune response against HIV-1 utilizing nucleic acids encoding polypeptides containing HIV-1 protease cleavage sites [patent_app_type] => utility [patent_app_number] => 16/810441 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 7961 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548161 [patent_doc_number] => 20220119502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => KAWASAKI DISEASE ANTIBODIES IDENTIFY HEPACIVIRUS PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/310832 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17619003 [patent_doc_number] => 11338030 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-24 [patent_title] => Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens [patent_app_type] => utility [patent_app_number] => 16/802805 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 26 [patent_no_of_words] => 30223 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16802805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19731122 [patent_doc_number] => 12209113 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => Methods and compositions for protection against lentiviral infections [patent_app_type] => utility [patent_app_number] => 16/787870 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 56 [patent_no_of_words] => 18394 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17577021 [patent_doc_number] => 20220133876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => NOVEL RECOMBINANT INFLUENZA VIRUS HAVING IMMUNE AND THERAPEUTIC RESPONSES TO HETEROLOGOUS INFLUENZA A VIRUS, AND GENETIC VECTOR AND THERAPEUTIC VACCINE COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/431070 [patent_app_country] => US [patent_app_date] => 2020-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17577017 [patent_doc_number] => 20220133872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => A MONOPHOSPHORYL LIPID-A LIPOSOME BASED CANCER VACCINE [patent_app_type] => utility [patent_app_number] => 17/429196 [patent_app_country] => US [patent_app_date] => 2020-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17938427 [patent_doc_number] => 11472868 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 [patent_app_type] => utility [patent_app_number] => 16/786821 [patent_app_country] => US [patent_app_date] => 2020-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 34 [patent_no_of_words] => 13711 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 209 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16786821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20115063 [patent_doc_number] => 12364747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Stabilized live attenuated influenza vaccine compositions [patent_app_type] => utility [patent_app_number] => 17/429965 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9982 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625746 [patent_doc_number] => 20220160761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => METHOD FOR T CELL ACTIVATION FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/429235 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625746 [patent_doc_number] => 20220160761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => METHOD FOR T CELL ACTIVATION FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/429235 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17580195 [patent_doc_number] => 20220137050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => METHOD FOR DIAGNOSING HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 (HTLV-1) ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/429206 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429206 [rel_patent_id] =>[rel_patent_doc_number] =>)